Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02625233 · ClinicalTrials.gov registry record · NA
Clinical Long-Term Evaluation of Approved and Investigational Contact Lenses
A NA study of Visual Disorders, sponsored by Johnson & Johnson Vision Care.
- Completed
- Registry status
- NA
- Development phase
- 105
- Enrollment target
- 6
- Study locations
NCT02625233: Completed NA study of Visual Disorders, sponsored by Johnson & Johnson Vision Care.
NCT02625233 is a NA study of Visual Disorders that has completed, run by Johnson & Johnson Vision Care. The registered enrollment target is 105 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02625233, a NA study of Visual Disorders, has completed, sponsored by Johnson & Johnson Vision Care.
- COMPLETED
- Registry status
- NA
- Development phase
- 105 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a multi-site, dispensing, 4-visit, 2-arm parallel group, randomized, double-masked clinical trial using a Vistakon investigational contact lens (test) and a marketed monthly replacement contact lens (control). Each subject will be assigned randomly to either the test or control lens to evaluate the long term safety and efficacy of the investigational contact lens compared to the marketed contact lens over a period of six months of lens wear.
Primary Outcome
Slit lamp findings were graded using a FDA Grade Scale, 0 = None, 1 = Slight, 2 = Moderate, 3 = Significant, 4 = Advanced. Measurements were taken in each subject eye at the initial visit, 4 month, 5 month and 6 month follow-up evaluations. This study is a continuation of a previous study therefore data from the initial visit was included in reporting. The proportion of subject eyes with SLF grade 3 or higher was reported for each lens.
Conditions Studied
Interventions
- DEVICE senofilcon C
- DEVICE comfilcon A
Study Locations (6)
Florida
- Vue Optical Boutique - Jacksonville
- Omega Vision Center, PA / Sabal Eye Care - Longwood
Illinois
- Eyecare Associates - Bloomington
New Jersey
- Dr. Debbie H. Kim, OD - Closter
New York
- Sacco Eye Group - Vestal
Utah
- Dr. William Bogus - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2015-10-01 |
| Est. Completion | 2016-02-01 |
| Phase | NA |
What the finished NCT02625233 record still lists
NCT02625233 is an interventional study that assigns participants to a tested intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Visual Disorders appearing as the primary indexed condition, and to 2 interventions - of which senofilcon C is the first listed.
NCT02625233 lists 6 locations in 5 states (Florida, Illinois, New Jersey).
Frequently Asked Questions
What is clinical trial NCT02625233 about?
NCT02625233 is a clinical study titled "Clinical Long-Term Evaluation of Approved and Investigational Contact Lenses". This is a multi-site, dispensing, 4-visit, 2-arm parallel group, randomized, double-masked clinical trial using a Vistakon investigational contact lens (test) and a marketed monthly replacement contact lens (control). Each subject will be assigned randomly to either the test or control lens to evalu...
What is the current status of trial NCT02625233?
This trial is currently completed. It is a NA study. The enrollment target is 105 participants. The study started on 2015-10-01. Estimated completion is 2016-02-01.
What conditions does trial NCT02625233 study?
This clinical trial studies the following conditions: Visual Disorders.
What interventions are being tested in trial NCT02625233?
The interventions under investigation include: senofilcon C (DEVICE), comfilcon A (DEVICE).
Who is sponsoring clinical trial NCT02625233?
This trial is sponsored by Johnson & Johnson Vision Care, which has 142 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02625233 being conducted?
This trial has 6 study locations across Florida, Illinois, New Jersey, New York, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02625233's enrollment target sits among peer trials
105 834th of 2000 higher than 1,165 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03372317 · 105 participants
Tau PET in Imaging and Cognition: Healthy Adults From 55-90
- NCT04253964 · 105 participants · Phase 2
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
- NCT04742452 · 105 participants · NA
Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears
- NCT04875429 · 105 participants · NA
Zenith® Fenestrated+ Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI